Completed

Personalized Translational Platform for Biomarker Discovery in Brain Tumors

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Astrocytoma+7

+ Glioblastoma

+ Glioma

From 18 to 85 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: December 2009
See protocol details

Summary

Principal SponsorMarcelo F. Di Carli, MD, FACC
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 1, 2009

Actual date on which the first participant was enrolled.

The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.

Official TitlePersonalized Translational Platform for Biomarker Discovery in Brain Tumors
NCT01240161
Principal SponsorMarcelo F. Di Carli, MD, FACC
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

37 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 85 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AstrocytomaGlioblastomaGliomaNeoplasmsNeoplasms by Histologic TypeNeoplasms, Germ Cell and EmbryonalNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueNeuroectodermal TumorsNeoplasms, Neuroepithelial

Criteria

5 inclusion criteria required to participate
Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT
Anticipated survival ≥6 months
Able to give informed consent
Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia
Show More Criteria
7 exclusion criteria prevent from participating
Prior radiation therapy and chemotherapy to the brain
Active intracranial infection or nonglial brain mass.
Recent large intracranial hemorrhage (<1 month)
Expected survival <6 months
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Suspended

University of California at San Diego

San Diego, United StatesOpen University of California at San Diego in Google Maps
Suspended

Brigham and Women's Hospital

Boston, United States
Completed2 Study Centers